Warner Bros. may reopen sale talks with Paramount following new deal terms, Bloomberg reports

Warner Bros. may reopen sale talks with Paramount following new deal terms, Bloomberg reports


The Warner Bros. logo is displayed on a water tower at Warner Bros. Studio on September 12, 2025 in Burbank, California.

Mario Tama | Getty Images

Warner Bros. Discovery‘s board is considering reopening sales talks with Paramount Skydance after recently receiving an amended offer with sweetened deal terms, Bloomberg News reported on Sunday, citing unnamed sources.

Warner Bros. in December agreed to sell both its film studio and HBO Max streaming service to Netflix for $27.75 per share. Paramount, which owns CBS and MTV, in December launched a hostile bid for Warner Bros., promising its shareholders $30 per share in an all-cash deal.

Last week, Paramount upped the ante, saying it would add a ticking fee of 25 cents a share to its offer for any delay in regulatory approval of the deal.

The ticking fee would be approximately $650 million in cash value per quarter for every quarter the deal has not closed by Dec. 31, 2026, CNBC.com previously reported.

Paramount also said it will cover a $2.8 billion termination fee paid to Netflix if the Warner Bros. deal is terminated. Paramount also said it will eliminate $1.5 billion in possible debt refinancing costs.

Both Paramount and Netflix have said they would be willing to raise their bids to secure the Warner Bros. deal, Bloomberg reported. However, this is the first time Warner Bros. has considered whether Paramount’s offer could either result in a better deal or prompt Netflix to offer better deal terms, according to the report.

Read the complete Bloomberg report here.

WATCH: Chadwick: This is a once-in-a-lifetime opportunity for Paramount

Chadwick: This is a once in a lifetime opportunity for Paramount



Source

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial
World

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning. Eli Lilly‘s stock […]

Read More
Sam Altman defends AI resource usage: Water concerns ‘fake,’ and ‘humans use energy too’
World

Sam Altman defends AI resource usage: Water concerns ‘fake,’ and ‘humans use energy too’

OpenAI CEO Sam Altman on Friday defended the resource demands of artificial intelligence, calling concerns about data centers’ water use “fake” and comparing the energy used by AI systems to that of humans. Altman was speaking on the sidelines of the India AI Impact summit in an interview with The Indian Express when he was […]

Read More
CNBC Daily Open: New Trump tariffs are up after U.S. Supreme Court strikes some down
World

CNBC Daily Open: New Trump tariffs are up after U.S. Supreme Court strikes some down

U.S. President Donald Trump speaks during the National Governors Association Evening Dinner and Reception in the East Room of the White House on February 21, 2026 in Washington, DC, U.S. Al Drago | Getty Images News | Getty Images The U.S. Supreme Court on Friday struck down much of President Donald Trump’s “reciprocal” tariffs, which […]

Read More